1. AHRO : Austin Health Research Online

Ashish Srinivasan

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Ashish Srinivasan
Full Name
Srinivasan, Ashish
 
Department
 
ORCID
Loading... 3 0 20 0 false

Publications

Results 1-20 of 23 (Search time: 0.011 seconds).

Publication YearTitleAuthor(s)
1Jan-2024Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.Con, Danny; Srinivasan, Ashish 
2Dec-2023Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis.Hilley, Patrick ; Con, Danny; Choy, Matthew C ; Srinivasan, Ashish ; De Cruz, Peter P 
31-Nov-2023The Role of Intestinal Ultrasound During Pregnancy in Patients With Inflammatory Bowel Disease.Andrew, Bridgette; Vasudevan, Abhinav ; Srinivasan, Ashish 
4Aug-2023Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.Eqbal, Ali; Hilley, Patrick ; Choy, Matthew C ; Srinivasan, Ashish ; De Cruz, Peter P 
5May-2023Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses.Srinivasan, Ashish ; De Cruz, Peter P ; Sam, Melissa; Toong, Catherine; van Langenberg, Daniel R
6Jun-2022Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.De Gregorio, Michael; Lee, Tanya; Krishnaprasad, Krupa; Amos, Gregory; An, Yoon-Kyo; Bastian-Jordan, Matthew; Begun, Jakob; Borok, Nira; Brown, Dougal J M; Cheung, Wa; Connor, Susan J; Gerstenmaier, Jan; Gilbert, Lauren E; Gilmore, Robert B ; Gu, Bonita; Kutaiba, Numan ; Lee, Allan; Mahy, Gillian; Srinivasan, Ashish ; Thin, Lena; Thompson, Alexander J; Welman, Christopher J; Yong, Eric X Z; De Cruz, Peter P ; van Langenberg, Daniel; Sparrow, Miles P; Ding, Nik S
715-Mar-2022Synchronous Multifocal Adenomatous Dysplasia and Post-transplant Lymphoproliferative Disorder Confined to the Colon in a Patient with Ulcerative Colitis After Liver Transplant.Peterson, Adam R; Srinivasan, Ashish ; Proud, David ; Jackett, Louise A ; Gow, Paul J ; De Cruz, Peter P ; Choy, Matthew C 
82-Feb-2022Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease.Srinivasan, Ashish ; Gilmore, Robert B ; van Langenberg, Daniel; De Cruz, Peter P 
92022Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.Gilmore, Robert B ; Hilley, Patrick ; Srinivasan, Ashish ; Choy, Matthew C ; De Cruz, Peter P 
10Sep-2021Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question.Srinivasan, Ashish ; van Langenberg, Daniel R
1119-Aug-2021Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.Hilley, Patrick ; Gilmore, Robert B ; Srinivasan, Ashish ; Choy, Matthew C ; De Cruz, Peter P 
1210-Aug-2021Higher anti-tumour necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas.De Gregorio, Michael; Lee, Tanya; Krishnaprasad, Krupa; Amos, Gregory; An, Yoon-Kyo; Bastian-Jordan, Matthew; Begun, Jakob; Borok, Nira; Brown, Dougal J M; Cheung, Wa; Connor, Susan J; Gerstenmaier, Jan; Gilbert, Lauren E; Gilmore, Robert B ; Gu, Bonita; Kutaiba, Numan ; Lee, Allan; Mahy, Gillian; Srinivasan, Ashish ; Thin, Lena; Thompson, Alexander J; Welman, Christopher J; Yong, Eric X Z; De Cruz, Peter P ; van Langenberg, Daniel; Sparrow, Miles P; Ding, Nik S
13Jun-2021Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.Gilmore, Robert B ; Hilley, Patrick ; Srinivasan, Ashish ; Choy, Matthew C ; Grace, Josephine A ; De Cruz, Peter P 
14May-2021Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease.Srinivasan, Ashish ; van Langenberg, Daniel; De Cruz, Peter P 
15May-2021Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.Srinivasan, Ashish ; Haifer, Craig; Thin, Lena
16Apr-2021Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach.Srinivasan, Ashish ; De Cruz, Peter P ; van Langenberg, Daniel R
1714-Aug-2020Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford.Pulusu, Samba Siva Reddy; Srinivasan, Ashish ; Krishnaprasad, Krupa; Cheng, Daniel; Begun, Jakob; Keung, Charlotte; Van Langenberg, Daniel; Thin, Lena; Mogilevski, Tamara; De Cruz, Peter P ; Radford-Smith, Graham; Flanagan, Emma; Bell, Sally; Kashkooli, Soleiman; Sparrow, Miles; Ghaly, Simon; Bampton, Peter; Sawyer, Elise; Connor, Susan; Rizvi, Quart-Ul-Ain; Andrews, Jane M; Mahy, Gillian; Chivers, Paola; Travis, Simon; Lawrance, Ian Craig
18Aug-2020Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?Srinivasan, Ashish ; De Cruz, Peter P ; van Langenberg, Daniel R
19Aug-2020Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.Srinivasan, Ashish ; De Cruz, Peter P ; van Langenberg, Daniel R
2017-Jul-2020Using Ustekinumab to Treat Crohn's Disease-Related Orofacial Granulomatosis: Two Birds, One Stone.Gilmore, Robert B ; Li Wai Suen, Christopher F D; Elliott, Tim; De Cruz, Peter P ; Srinivasan, Ashish